Drug Eluting Balloon Market: Accelerating Growth Towards US$ 1.0 Bn, Expanding at a CAGR of 7.1% by 2031 - TMR Insights

The drug eluting balloon (DEB) market has emerged as a vital segment in the interventional cardiology and peripheral artery disease (PAD) treatment landscape. The increasing prevalence of cardiovascular disorders and the demand for minimally invasive treatment options have propelled the adoption of DEBs globally.

The global drug eluting balloon market was valued at US$ 571.1 million in 2022 and is projected to expand at a CAGR of 7.1% from 2023 to 2031, reaching approximately US$ 1.0 billion by the end of 2031. The market's growth is fueled by advancements in medical technology, increasing preference for non-stent-based treatment alternatives, and rising awareness about effective cardiovascular care.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Analyst Viewpoint

Experts anticipate significant expansion in the DEB market due to the rising burden of cardiovascular diseases, an aging population, and technological innovations in catheter-based treatment approaches. While the market faces challenges such as regulatory hurdles and high device costs, increased research funding and favorable reimbursement policies are expected to drive further adoption.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases - Increased cases of coronary and peripheral artery diseases boost demand.

Advancements in Balloon Catheter Technology - Development of next-generation DEBs enhances treatment efficacy.

Growing Preference for Minimally Invasive Procedures - Reduced recovery time and lower complication risks attract more patients.

Favorable Reimbursement Policies - Increased insurance coverage supports patient affordability and access.

Surge in Clinical Trials and Approvals - Continuous R&D efforts improve product innovation and regulatory acceptance.

Recent Developments

2023: Medtronic launched an advanced paclitaxel-coated DEB for peripheral artery disease treatment.

2022: Boston Scientific expanded its product portfolio with a new FDA-approved DEB for coronary interventions.

2021: B. Braun received regulatory clearance in Europe for its next-generation DEB featuring improved drug delivery.

2020: Abbott collaborated with leading research institutions to explore novel drug formulations for DEBs.

2019: BD acquired a medical device firm to strengthen its interventional cardiology segment.

Key Players

Bayer AG
Medtronic
B. Braun Melsungen AG
Cook Medical, Inc.
Boston Scientific Corporation
Becton, Dickson and Company
EuroCor
Terumo Corporation
Koninklijke Philips N.V.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Market Trends and Opportunities

Adoption of Biodegradable Drug Coatings - Next-gen DEBs with bioresorbable coatings gaining traction.

Growing Focus on Emerging Markets - Expanding healthcare infrastructure in Asia-Pacific and Latin America.

Expansion of Indications Beyond Cardiology - Increasing DEB use in vascular and non-vascular interventions.

Rising Investment in R&D - Companies investing in novel drug combinations to enhance efficacy.

Collaborations Between MedTech Firms and Hospitals - Partnerships driving innovation and clinical adoption.

Market Segmentation

By Application

Coronary Artery Disease
Peripheral Artery Disease

By End-Use

Hospitals
Specialty Clinics
Ambulatory Surgical Centers

Future Outlook

The drug eluting balloon market is poised for robust growth, driven by continuous technological advancements and expanding treatment applications. As healthcare providers and policymakers emphasize minimally invasive solutions, the demand for DEBs is expected to rise steadily in the coming years.

Regional Analysis

North America - Leading market due to high adoption rates and advanced healthcare infrastructure.

Europe - Significant growth driven by regulatory approvals and reimbursement policies.

Asia-Pacific - Fastest-growing region with increasing investments in cardiovascular healthcare.

Latin America & Middle East & Africa - Emerging markets with untapped potential for DEB adoption.

Explore Latest Research Reports by Transparency Market Research:

Hormone Replacement Therapy Market: https://www.pharmiweb.com/press-release/2025-03-12/hormone-replacement-therapy-market-to-reach-us-388-billion-by-2034-driven-by-increasing-demand-for-menopause-and-endocrine-disorder-treatments-tm

Sexually Transmitted Diseases (STD) Diagnostics Market: https://www.pharmiweb.com/press-release/2025-03-12/sexually-transmitted-diseases-std-diagnostics-market-to-exceed-us-159-billion-by-2034-fueled-by-innovation-and-rising-awareness-tmr-insights

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.